<DOC>
	<DOCNO>NCT02946073</DOCNO>
	<brief_summary>This study Phase III , placebo-controlled , multicenter study enriched-enrollment withdrawal design evaluate efficacy safety CAM2038 opioid-experienced subject moderate severe CLBP require continuous , around-the-clock ( ATC ) opioid treatment . The study comprise 5 phase : Screening Phase ( 2 week ) , Transition Phase ( 2 week ) , open label Titration Phase ( 10 week ) , Double-Blind Phase include Final Study Visit ( 12 week ) , Follow-up Phase ( 4 week ) . The overall duration participation 32 week , Screening Phase Follow Phase , include 12 week double-blinded treatment .</brief_summary>
	<brief_title>Buprenorphine ( CAM2038 ) Subjects With Recent History Moderate Severe Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Body mass index ( BMI ) 18 38 kg/m2 , inclusive . Clinical diagnosis recent history moderate severe Chronic Lower Back Pain ( CLBP ) minimum 3 month prior Screening . The pain must occur area boundary lowest rib immediately knee radiculopathy . Subjects must stable dose great equal 80 mg/day oral morphine Morphine Equivalent Dose ( MED ) 14 day prior Screening , despite prior dose escalation , receive adequate pain relief . Positive hepatitis B surface antigen , antibody hepatitis C virus , antibody human immunodeficiency virus ( HIV ) . Currently use fentanyl ( formulation ) use fentanyl within last 30 day . Clinically significant symptom , medical condition , circumstance , opinion Investigator , would preclude compliance protocol , adequate cooperation study , obtain informed consent , may prevent subject safely participate study Current Diagnostic Statistical Manual Mental Disorders ( DSMV ) , Fifth Edition diagnosis moderate severe substance use disorder ( include alcohol ) caffeine nicotine currently treat primary substance use disorder . Surgical procedure ( ) back pain within 6 month prior Screening . Concomitant disease ( ) could prolong QTcF interval autonomic neuropathy ( cause diabetes Parkinson 's disease ) , human immunodeficiency virus , cirrhosis , Long QT Syndrome , family history Long QT Syndrome . Screening QTcF &gt; 450ms male &gt; 470 m female clinically significant abnormality 12lead electrocardiogram ( ECG ) . A nerve plexus block , include epidural steroid injection facet block , within 1 month prior Screening botulinum toxin injection lower back region within 3 month Screening . Any chronic pain condition would interfere assessment Chronic Lower Back Pain ( CLBP ) . An active pending workman 's compensation , insurance claim , litigation relate back pain ( i.e. , primary claim back pain ) . Intake agent strong inhibitor inducer cytochrome P450 3A4 ( CYP3A4 ) azole antifungal ( e.g. , ketoconazole ) , macrolide antibiotic ( e.g. , clarithromycin ) , protease inhibitor ( e.g. , ritonavir , indinavir , saquinavir ) least 30 day prior Screening . CYP3A4 inhibitor prohibit 30 day last dose CAM2038 . Has significant renal hepatic disease , indicate clinical laboratory assessment result ( aspartate aminotransferase , alanine aminotransferase , lactate dehydrogenase value great equal 3 × upper limit normal [ ULN ] , creatinine value great equal 1.5 × ULN ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>